Palatin Technologies 500%+ Expected Return
Company Profile
Sector: Health Care
Industry: Biotechnology
Company Location: Cranbury, NJ
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor
12 Month Price Targets:
High: $5.00
Mean: $3.00
Low: $2.00
News:
--HC Wainwright Adjusts Palatin Technologies' Price Target to $5 From $2, Keeps Buy Rating
MT NEWSWIRES 7:18 AM ET 11/24/2021
07:18 AM EST, 11/24/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: www.mtnewswires.com/contact-us)
Price: 0.3800, Change: +0.04, Percent Change: +10.34
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
Sector: Health Care
Industry: Biotechnology
Company Location: Cranbury, NJ
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor
12 Month Price Targets:
High: $5.00
Mean: $3.00
Low: $2.00
News:
--HC Wainwright Adjusts Palatin Technologies' Price Target to $5 From $2, Keeps Buy Rating
MT NEWSWIRES 7:18 AM ET 11/24/2021
07:18 AM EST, 11/24/2021 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: www.mtnewswires.com/contact-us)
Price: 0.3800, Change: +0.04, Percent Change: +10.34
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.